Both journals are anchored in large scientific societies and serve basically the same medical , physical and biological community and at the same scientific level ; the two journals are in the most recent Impact Factor list ranked almost back to back , indicating an equal importance and contribution to science .
Radiotherapy and Oncology is more than a scientific journal , it also serves other purpose s such as facilitate education through ( educational ) review s and improving the st and ard of care by bringing forward guidelines for conduct of radiotherapy .
Finally , the journal also tries to maintain a communication platform between the science produced by the membership of ESTRO and therefore it brings papers frommembers in the different European countries , sometimes at the expense of ultimate scientific quality , but with the underst and ing that it is important that the entire ESTRO membership gets access and opportunity to publish in a high ranked journal .
ESTRO , the European Society for Therapeutic Radiation Oncology , or with its new name European Society for Radiation Oncology , is a scientific society .
It means that the prime aim of ESTRO is to bring to bring people together on an individual basis who have a common interest in improving the scientific conduct of radiotherapy and cancer treatment in Europe by ensuring that proper radiotherapy is available in the multidisciplinary treatment of cancer and applied with the right indication and with the most optimal technique .
One of the main aims of this endeavour was to create a platform for scientific exchange through meetings and through the establishment of a scientific journal [ 1 ] .
Thus Radiotherapy and Oncology was launched shortly after the foundation of ESTRO and has become the society ’s prime vehicle for scientific communication by serving ESTRO members through almost the entire 30 years of the society ’s existence .
The aim was to create a peer review ed high quality international journal and that aim has indeed been fulfilled . ‘ ‘
Rectal cancer multidisciplinary management: evidences and future landscape.
In the last two decades we have seen major advances in the way patients with rectal cancer are investigated and treated . Three key components , which have all been led by European investigators , are the well-documented improvements in pre-operative staging , improvements in surgical technique and histopathological assessment of the resected specimen [ 1 ] . Key studies have vali date d the importance of cross-sectional pelvic imaging , particularly phased array MRI and its ability to demonstrate the relationship of the macroscopic tumour to the surrounding well-defined anatomical plane of surgical excision . This development is closely linked with the ability of relatively simple histopathological techniques to assess and measure the distance of microscopic tumour to the circumferential resection margin ( CRM ) of the resected rectal cancer specimen [ 2,3 ] . The third key component is the recognition of the importance of the technique of rectal cancer surgery . The concept of ‘ ‘ mesorectal excision ” where meticulous dissection of the anatomical plane surrounding the mesorectal fat is of crucial importance and has been reported to result in significantly lower rates of local recurrence in specialist centres , population -based audit and within the framework of r and omised controlled trials [ 4 ] . In addition , European investigators have continued to test important questions in the framework of r and omised phase III trials with a specific focus on the role of adjuvant radiotherapy . In the last nine years at least seven European phase III trials evaluating the role of adjuvant radiotherapy in rectal cancer have been published . From these trials , we have an evidence base that demonstrates the efficacy of both short course pre-operative radiotherapy and pre-operative concurrent radiochemotherapy [ 5–11 ] . Despite a major increase in our knowledge we are aware of a wide variation in both opinion and practice within and between European ( and other ) countries . In the United States , the NIH consensus statement was published in 1990 and it had a major influence on North American practice . The EURECA project was proposed to identify the degree of consensus that could be achieved across a wide range of topics relating to the management of rectal cancer and of equal importance to identify areas where future research is a priority . The process anticipated a range of views amongst both experts and the health care professionals who
Both journals are anchored in large scientific societies and serve basically the same medical , physical and biological community and at the same scientific level ; the two journals are in the most recent Impact Factor list ranked almost back to back , indicating an equal importance and contribution to science .
Radiotherapy and Oncology is more than a scientific journal , it also serves other purpose s such as facilitate education through ( educational ) review s and improving the st and ard of care by bringing forward guidelines for conduct of radiotherapy .
Finally , the journal also tries to maintain a communication platform between the science produced by the membership of ESTRO and therefore it brings papers frommembers in the different European countries , sometimes at the expense of ultimate scientific quality , but with the underst and ing that it is important that the entire ESTRO membership gets access and opportunity to publish in a high ranked journal .
ESTRO , the European Society for Therapeutic Radiation Oncology , or with its new name European Society for Radiation Oncology , is a scientific society .
It means that the prime aim of ESTRO is to bring to bring people together on an individual basis who have a common interest in improving the scientific conduct of radiotherapy and cancer treatment in Europe by ensuring that proper radiotherapy is available in the multidisciplinary treatment of cancer and applied with the right indication and with the most optimal technique .
One of the main aims of this endeavour was to create a platform for scientific exchange through meetings and through the establishment of a scientific journal [ 1 ] .
Thus Radiotherapy and Oncology was launched shortly after the foundation of ESTRO and has become the society ’s prime vehicle for scientific communication by serving ESTRO members through almost the entire 30 years of the society ’s existence .
The aim was to create a peer review ed high quality international journal and that aim has indeed been fulfilled . ‘ ‘